CCS 2025: Identifying keratoconus in patients through successful comanagement

News
Video

Peter Hersh, MD, stated that the key takeaway from a handful of presentations he gave at CCS 2025 is that successfully treating patients with keratoconus is identifying the disease early.

Presentations that Peter Hersh, MD, gave at the Collaborative Care Symposium (CCS) 2025 on May 31 focused on keratoconus, a progressive corneal disease that requires early detection and specialized management. He spoke on keratoconus and complex refractive surgery and corneal cross-linking with John Gelles, OD, FAAO, and Steven Greenstein, MD.

Hersh emphasizes the critical importance of identifying keratoconus in younger patients, particularly those diagnosed in their early teens, who are most likely to experience rapid disease progression. Primary eye care providers should be vigilant in screening for keratoconus, recognizing that it is more prevalent in younger populations compared to conditions like glaucoma or retinal disorders. Key diagnostic indicators include patients whose vision cannot be corrected to 20/20 through standard refraction, unusual astigmatism patterns, and irregular keratometric measurements. Advanced diagnostic tools are crucial in identifying keratoconus. Corneal topography and tomography are considered the gold standard for diagnosis, allowing practitioners to detect subtle corneal changes that might indicate the disease's onset. Hersh strongly recommended thorough screening when standard vision correction methods prove ineffective. Interdisciplinary collaboration is paramount in managing keratoconus.

Optometrists, ophthalmologists, and surgeons must work together to ensure comprehensive patient care. This collaborative approach is especially critical for early intervention strategies like corneal cross-linking, which can significantly improve patient prognosis when implemented early. Long-term patient management is another crucial aspect discussed. Keratoconus patients require ongoing monitoring, typically with yearly examinations. Contact lens fitting remains a primary treatment modality, and patients will need specialized care throughout their lives. As patients age, additional challenges emerge, such as difficulty managing contact lenses and preparing for potential procedures like cataract surgery. Hersh highlighted emerging innovative treatments that can enhance patient outcomes, including CTAK and topography-guided PRK. These techniques can improve corneal curvature and optical focus, offering new hope for patients as they navigate the complexities of keratoconus across different life stages.

Ultimately, Hersh underscored the need for heightened awareness, early detection, continuous education, and collaborative medical approaches to effectively manage keratoconus and improve patients' quality of life.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Mitch Ibach, OD, FAAO, details the importance to unveiling the underlying cause of dry eye in a CCS 2025 presentation.
Steven Greenstein, MD, one of the cochairs of the Collaborative Care Symposium gave some insight into the upcoming conference and what attendees can expect.
Dr Julie Poteet reports on patient-reported outcomes using lipid-containing artificial tear
Susana Marcos, PhD, discusses the implications her research presents for the role optical coherence tomography (OCT) could play in presbyopia and myopia accommodation efforts.
Susana Marcos, PhD, outlines a presentation she gave at ARVO 2025 on a unique utilization of optical coherence tomography.
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
© 2025 MJH Life Sciences

All rights reserved.